Bionano Genomics, Inc. (NASDAQ:BNGO) Short Interest Up 25.1% in December

Bionano Genomics, Inc. (NASDAQ:BNGO) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 15,840,000 shares, an increase of 25.1% from the November 30th total of 12,660,000 shares. Approximately 15.6% of the company’s shares are sold short. Based on an average trading volume of 2,880,000 shares, the days-to-cover ratio is currently 5.5 days.

Institutional Investors Weigh In On Bionano Genomics

Institutional investors have recently bought and sold shares of the stock. GSA Capital Partners LLP purchased a new stake in Bionano Genomics in the 3rd quarter worth approximately $46,000. Armistice Capital LLC bought a new stake in Bionano Genomics in the 2nd quarter worth $1,138,000. Carret Asset Management LLC lifted its position in Bionano Genomics by 89.0% during the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after acquiring an additional 40,055 shares during the period. Finally, Geode Capital Management LLC raised its stake in Bionano Genomics by 47.3% during the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock valued at $401,000 after buying an additional 283,639 shares during the last quarter. Institutional investors own 11.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. BTIG Research downgraded Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Tuesday, September 10th. LADENBURG THALM/SH SH lowered shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Friday, November 15th.

Bionano Genomics Price Performance

Shares of BNGO opened at $0.29 on Tuesday. The stock has a market cap of $29.18 million, a P/E ratio of -0.12 and a beta of 2.28. The business’s fifty day moving average is $0.25 and its 200 day moving average is $0.43. The company has a quick ratio of 0.99, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. Bionano Genomics has a 12-month low of $0.19 and a 12-month high of $2.16.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.